Literature DB >> 1970235

Desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of pindolol and celiprolol in rats.

C Nanoff1, M Ströher, H Haschkowitz, W Schütz, H Pittner.   

Abstract

The regulatory effects of pindolol and celiprolol on cardiac beta-adrenoceptor density were studied in vivo in order to assess the subtype selectivity of their partial agonistic activity (PAA). The substances were continuously administered to rats for 1 week by means of implanted osmotic minipumps. The density of beta-adrenoceptor subtypes were estimated from ICYP saturation binding experiments performed on cardiac ventricular plasma membranes in the presence of a highly selective antagonist (CGP 20172 A or ICI 118,551). Both antagonists were employed at concentrations as high as to block one subtype only without affecting the complementary subtype. For control purposes, rats were also treated with isoprenaline (0.4 mg/kg/h) and propranolol (0.15 mg/kg/h), or vehicle. Pindolol (0.036 mg/kg/h) and celiprolol (0.36 mg/kg/h) reduced the density of ventricular beta 2-adrenoceptors by 46% and 23%, respectively, which--in the case of pindolol--was significant when compared to the non-treated controls. Both compounds, however, produced a small, but distinct increase in the number of beta 1-adrenoceptors by approximately 26%. This finding is in contrast to the propranolol--induced up-regulation of both beta 1- and beta 2-adrenoceptors by approximately 80%. Since supramaximal doses of each drug were administered, a significant smaller increase of beta 1-adrenoceptors by pindolol and celiprolol--as compared to the increase produced by propranolol--can be interpreted as evidence for a PAA of pindolol and celiprolol on beta 1-adrenoceptors as well. Isoprenaline as a full agonist caused a marked loss of of both beta-adrenoceptor subtypes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970235     DOI: 10.1007/bf01907017

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  22 in total

Review 1.  The additional properties of beta adrenoceptor blocking drugs.

Authors:  B N Prichard; B Tomlinson
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  A different desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of isoprenaline.

Authors:  C Nanoff; M Freissmuth; E Tuisl; W Schütz
Journal:  J Cardiovasc Pharmacol       Date:  1989-02       Impact factor: 3.105

3.  CGP 20712 A: a useful tool for quantitating beta 1- and beta 2-adrenoceptors.

Authors:  D J Dooley; H Bittiger; N C Reymann
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

Review 4.  The beta-adrenergic blockade withdrawal phenomenon.

Authors:  B N Prichard; B Tomlinson; R J Walden; P Bhattacharjee
Journal:  J Cardiovasc Pharmacol       Date:  1983       Impact factor: 3.105

5.  Effects of pindolol and propranolol on beta adrenergic receptors on human lymphocytes.

Authors:  A Hedberg; J G Gerber; A S Nies; B B Wolfe; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

6.  Cardiac ventricular beta 2-adrenoceptors in guinea-pigs and rats are localized on the coronary endothelium.

Authors:  M Freissmuth; V Hausleithner; S Nees; M Böck; W Schütz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-09       Impact factor: 3.000

7.  Selective desensitization of cardiac beta adrenoceptors by prolonged in vivo infusion of catecholamines in rats.

Authors:  H Y Chang; R M Klein; G Kunos
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

8.  Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.

Authors:  P E Hicks; I Cavero; P Manoury; F Lefevre-Borg; S Z Langer
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

9.  Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.

Authors:  R G Van Inwegen; A Khandwala; I Weinryb; T P Pruss; E Neiss; C A Sutherland
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-11

10.  The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.

Authors:  T Abrahamsson
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

View more
  5 in total

Review 1.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

2.  Celiprolol exerts microvascular dilatation by activation of beta 2-adrenoceptors.

Authors:  S Dhein; S Titzer; M Wallstein; A Müller; R Gerwin; B Panzner; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

Review 3.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 4.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

5.  Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells.

Authors:  Martina B Michel-Reher; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-12       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.